Dysregulated B Cell Expression of RANKL and OPG Correlates with Loss of Bone Mineral Density in HIV Infection

English version České info

HIV infection causes significant bone loss and skeletal deterioration, leading to fractures that are often devastating and incur significant financial burden on patients and their families. HIV-infected individuals have up to a five-fold higher risk of bone fractures, and the increasing average age of people living with HIV/AIDS has triggered fears of an impending epidemic of bone fractures in this population. Antiretroviral therapy, used to manage HIV infection, fails to prevent, but rather paradoxically accelerates skeletal decline. The underlying mechanisms of HIV-induced bone loss are poorly understood. The aim of this study was to clarify the mechanisms of bone loss in HIV-infected patients, in an effort to better understand how bone loss and fractures occur, and consequently how it can be prevented in this population. The cytokine RANKL (Receptor Activator of Nuclear Factor kappa-B Ligand) helps induce bone loss. We show that RANKL expression was increased in immune cells in HIV-infected individuals. Another cytokine, osteoprotegerin (OPG), counteracts the activity of RANKL, and therefor helps prevent bone loss. OPG expression by the same immune cells was decreased in HIV-infected individuals. We conclude that disrupted immune cell expression of RANKL and OPG in HIV-infected patients contributes to bone loss.

Vyšlo v časopise: Dysregulated B Cell Expression of RANKL and OPG Correlates with Loss of Bone Mineral Density in HIV Infection. PLoS Pathog 10(11): e32767. doi:10.1371/journal.ppat.1004497
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004497

Souhrn

Zdroje

1. GandhiRT, SaxPE, GrinspoonSK (2012) Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age. J Infect Dis 205 Suppl 3S353–354.

2. GuaraldiG, OrlandoG, ZonaS, MenozziM, CarliF, et al. (2011) Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 53: 1120–1126.

3. TebasP, PowderlyWG, ClaxtonS, MarinD, TantisiriwatW, et al. (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14: F63–67.

4. BrownTT, QaqishRB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20: 2165–2174.

5. McComseyGA, TebasP, ShaneE, YinMT, OvertonET, et al. (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clinical infectious diseases 51: 937–946.

6. BrueraD, LunaN, DavidDO, BergoglioLM, ZamudioJ (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17: 1917–1923.

7. GrijsenML, VrouenraetsSM, SteingroverR, LipsP, ReissP, et al. (2010) High prevalence of reduced bone mineral density in primary HIV-1-infected men. Aids 24: 2233–2238.

8. MondyK, YarasheskiK, PowderlyWG, WhyteM, ClaxtonS, et al. (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36: 482–490.

9. SchaferJJ, ManlangitK, SquiresKE (2013) Bone health and human immunodeficiency virus infection. Pharmacotherapy 33: 665–682.

10. BollandMJ, GreyA (2011) HIV and Low Bone Density: Responsible Party, or Guilty by Association? IBMS BoneKEy 8: 7–15.

11. GuaraldiG, VenturaP, AlbuzzaM, OrlandoG, BediniA, et al. (2001) Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS 15: 137–138.

12. TriantVA, BrownTT, LeeH, GrinspoonSK (2008) Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 93: 3499–3504.

13. Young B, Dao CN, Buchacz K, Baker R, Brooks JT (2011) Increased Rates of Bone Fracture among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared with the US General Population, 2000–2006. Clin Infect Dis. 2011/03/15 ed.

14. WomackJA, GouletJL, GibertC, BrandtC, ChangCC, et al. (2011) Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 6: e17217.

15. PriorJ, BurdgeD, MaanE, MilnerR, HankinsC, et al. (2007) Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 18: 1345–1353.

16. Guerri-FernandezR, VestergaardP, CarbonellC, KnobelH, AvilesFF, et al. (2013) HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study. J Bone Miner Res 28: 1259–1263.

17. TeitelbaumSL (2000) Bone resorption by osteoclasts. Science 289: 1504–1508.

18. KhoslaS (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142: 5050–5055.

19. YunTJ, ChaudharyPM, ShuGL, FrazerJK, EwingsMK, et al. (1998) OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 161: 6113–6121.

20. ToraldoG, RoggiaC, QianWP, PacificiR, WeitzmannMN (2003) IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A 100: 125–130.

21. WeitzmannMN (2013) The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica 2013: 1–29.

22. WeitzmannMN, PacificiR (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116: 1186–1194.

23. MoirS, HoJ, MalaspinaA, WangW, DiPotoAC, et al. (2008) Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 205: 1797–1805.

24. DayCL, KaufmannDE, KiepielaP, BrownJA, MoodleyES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350–354.

25. VikulinaT, FanX, YamaguchiM, Roser-PageS, ZayzafoonM, et al. (2010) Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A 107: 13848–13853.

26. LiY, ToraldoG, LiA, YangX, ZhangH, et al. (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109: 3839–3848.

27. OnalM, XiongJ, ChenX, ThostensonJD, AlmeidaM, et al. (2012) Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem 287: 29851–29860.

28. KawaiT, MatsuyamaT, HosokawaY, MakihiraS, SekiM, et al. (2006) B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 169: 987–998.

29. MoirS, FauciAS (2009) B cells in HIV infection and disease. Nat Rev Immunol 9: 235–245.

30. TitanjiK, De MilitoA, CagigiA, ThorstenssonR, GrutzmeierS, et al. (2006) Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 108: 1580–1587.

31. ManolagasSC, JilkaRL (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332: 305–311.

32. ShimizuY, SakaiA, MenukiK, MoriT, IsseT, et al. (2011) Reduced bone formation in alcohol-induced osteopenia is associated with elevated p21 expression in bone marrow cells in aldehyde dehydrogenase 2-disrupted mice. Bone 48: 1075–1086.

33. CollinF, DuvalX, Le MoingV, PirothL, Al KaiedF, et al. (2009) Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 23: 1021–1024.

34. CotterAG, SabinCA, SimelaneS, MackenA, KavanaghE, et al. (2014) Relative contribution of HIV infection, demographics and body mass index to bone mineral density. AIDS 28: 2051–2060.

35. HuiSL, SlemendaCW, JohnstonCCJr (1988) Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81: 1804–1809.

36. AroraS, AgrawalM, SunL, DuffooF, ZaidiM, et al. (2010) HIV and bone loss. Current osteoporosis reports 8: 219–226.

37. GibelliniD, BorderiM, De CrignisE, CicolaR, VesciniF, et al. (2007) RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol 79: 1446–1454.

38. DolanSE, HuangJS, KillileaKM, SullivanMP, AliabadiN, et al. (2004) Reduced bone density in HIV-infected women. Aids 18: 475–483.

39. UelandT, BollerslevJ, GodangK, MullerF, FrolandSS, et al. (2001) Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess–possible role in bone homeostasis. Eur J Endocrinol 145: 685–690.

40. HwangJJ, WeiJ, AbbaraS, GrinspoonSK, LoJ (2012) Receptor activator of nuclear factor-kappaB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients. J Acquir Immune Defic Syndr 61: 359–363.

41. BrownTT, ChenY, CurrierJS, RibaudoHJ, RothenbergJ, et al. (2013) Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 63: 323–330.

42. KanisJA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359: 1929–1936.

43. Eghbali-FatourechiG, KhoslaS, SanyalA, BoyleWJ, LaceyDL, et al. (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111: 1221–1230.